[go: up one dir, main page]

AR072135A1 - Formas de dosificacion de fenofibrato - Google Patents

Formas de dosificacion de fenofibrato

Info

Publication number
AR072135A1
AR072135A1 ARP090101116A ARP090101116A AR072135A1 AR 072135 A1 AR072135 A1 AR 072135A1 AR P090101116 A ARP090101116 A AR P090101116A AR P090101116 A ARP090101116 A AR P090101116A AR 072135 A1 AR072135 A1 AR 072135A1
Authority
AR
Argentina
Prior art keywords
fenofibrate
particles
dosage forms
physiological conditions
dosage form
Prior art date
Application number
ARP090101116A
Other languages
English (en)
Inventor
Michael John Wilkins
Tuula Ryde
Evan E Gustow
Stephen B Ruddy
Rakesh Patel
Niels P Ryde
Rajeev Jain
Original Assignee
Fournier Lab Ireland Ltd
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd, Elan Pharma Int Ltd filed Critical Fournier Lab Ireland Ltd
Publication of AR072135A1 publication Critical patent/AR072135A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Metodos in vitro para evaluar la efectividad in vivo de formas de dosis del fibrato, tal como fenofibrato. Los metodos utilizan medios representativos en condiciones fisiologicas humanas in vivo. Reivindicacion 1: Una forma de dosificacion de fenofibrato caracterizada porque comprende: part¡culas que consisten en fenofibrato; y al menos un estabilizador de superficie adsorbido en la superficie de las part¡culas, en donde despues de la reconstitucion en un medio acuoso de relevancia biologica que imita las condiciones fisiologicas humanas, las part¡culas de fenofibrato se caracterizan por una distribucion de tamano de part¡cula estable que tiene un tamano de part¡cula promedio efectivo de menos de 2000 nm. Reivindicacion 25: La forma de dosificacion de la reivindicacion 1 caracterizada porque adem s comprende uno o m s agentes activos seleccionados del grupo que consiste en agentes antihiperglucemicos, estatinas, inhibidores de HMGCoA reductasa y antihipertensivos.
ARP090101116A 2008-03-28 2009-03-27 Formas de dosificacion de fenofibrato AR072135A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/058,497 US20080241070A1 (en) 2000-09-21 2008-03-28 Fenofibrate dosage forms

Publications (1)

Publication Number Publication Date
AR072135A1 true AR072135A1 (es) 2010-08-11

Family

ID=40846436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101116A AR072135A1 (es) 2008-03-28 2009-03-27 Formas de dosificacion de fenofibrato

Country Status (7)

Country Link
US (1) US20080241070A1 (es)
EP (1) EP2271316A2 (es)
JP (1) JP2011516421A (es)
AR (1) AR072135A1 (es)
CA (1) CA2719811A1 (es)
TW (1) TW201006466A (es)
WO (1) WO2009120919A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
DK2398476T3 (en) 2009-02-23 2018-04-16 Nanorx Inc POLICOSANOL NANOPARTICLES
US9034383B2 (en) 2010-08-23 2015-05-19 NanoRx, Inc. Policosanol nanoparticles
US9232790B2 (en) * 2011-08-02 2016-01-12 Kimberly-Clark Worldwide, Inc. Antimicrobial cleansing compositions
US20140255480A1 (en) * 2011-09-07 2014-09-11 Ethypharm Pharmaceutical formulation of nanonized fenofibrate
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
WO2014003706A1 (en) * 2012-06-25 2014-01-03 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) * 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
WO2015167557A1 (en) 2014-04-30 2015-11-05 Kimberly-Clark Worldwide, Inc. Topical compositions for stimulating adipogenesis and lipogenesis to reduce the signs of skin aging
KR102246477B1 (ko) 2014-04-30 2021-04-30 킴벌리-클라크 월드와이드, 인크. 피부 노화의 징후를 감소시키는 방법
AU2014392629B2 (en) 2014-04-30 2021-04-01 Kimberly-Clark Worldwide, Inc. Use of Undaria extract to reduce signs of skin aging
WO2015167542A2 (en) 2014-04-30 2015-11-05 Kimberly-Clark Worldwide, Inc. Compositions and methods for reducing oxidative stress
ES2984690T3 (es) 2020-06-26 2024-10-30 Algiax Pharmaceuticals Gmbh Composición de nanopartículas
WO2022183281A1 (en) * 2021-03-03 2022-09-09 Mcmaster Christopher R Compounds and treatments for muscular dystrophy

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907792A (en) * 1969-01-31 1975-09-23 Andre Mieville Phenoxy-alkyl-carboxylic acid derivatives and the preparation thereof
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH06511481A (ja) * 1991-07-05 1994-12-22 ユニバーシティ オブ ロチェスター 気泡を取り込む超微小非凝集多孔質粒子
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
DE4406239C1 (de) * 1994-02-25 1995-06-14 Lucas Dipl Ing Menke Vorrichtung und Verfahren zur Trennung von Substanzen aus einem Fluid mittels Druckentspannungsflotation
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
WO1999049846A2 (en) * 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
ES2194477T3 (es) * 1998-06-19 2003-11-16 Skyepharma Canada Inc Procedimiento para generar particulas de compuestos insolubles en agua con un tamaño de hasta 2000 nm.
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6383517B1 (en) * 1999-01-29 2002-05-07 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6719999B2 (en) * 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6431478B1 (en) * 1999-06-01 2002-08-13 Elan Pharma International Limited Small-scale mill and method thereof
US6368620B2 (en) * 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
EP1276465B1 (en) * 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
CN1211164C (zh) * 2000-05-10 2005-07-20 斯凯伊药品加拿大公司 介质研磨
US6696084B2 (en) * 2000-09-20 2004-02-24 Rtp Pharma Inc. Spray drying process and compositions of fenofibrate
ATE522211T1 (de) * 2000-09-20 2011-09-15 Jagotec Ag Stabilisierte fibrat-mikropartikel
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
ES2284646T3 (es) * 2001-02-22 2007-11-16 Jagotec Ag Combinaciones de estatina-fibrato con efectos secundarios en ayunas-alimentado reducidos.
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions

Also Published As

Publication number Publication date
CA2719811A1 (en) 2009-10-01
JP2011516421A (ja) 2011-05-26
TW201006466A (en) 2010-02-16
WO2009120919A3 (en) 2010-11-04
EP2271316A2 (en) 2011-01-12
US20080241070A1 (en) 2008-10-02
WO2009120919A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
AR072135A1 (es) Formas de dosificacion de fenofibrato
Hasan et al. Antiviral nanostructured surfaces reduce the viability of SARS-CoV-2
Fabrega et al. Interactions of silver nanoparticles with Pseudomonas putida biofilms
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
Kiser et al. Titanium nanomaterial removal and release from wastewater treatment plants
ES2504175T3 (es) Composición limpiadora de superficies duras ácida y líquida
AR058519A1 (es) Particulas que interrumpen o impiden la adhesion bacteriana composiciones y metodos relacionados
AR055435A1 (es) Administacion de inhibidores de dipeptidil peptidasa
CL2012000469A1 (es) Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
MX2010004900A (es) Composiciones de eter-sulfoalquilico-ciclodextrina.
UY33637A (es) Metodos y composiciones que contienen jasmonato o compuestos relacionados para promover la actividad de biodefensa en las plantas
AR071174A1 (es) Uso de citrato como agente limpiador para superficies duras
MX2009002936A (es) Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
AR089007A1 (es) Composicion aditiva para fluidos de tratamiento de pozos
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CR11681A (es) Compuestos heterociclicos novedosos y usos de los mismos
MX2010003011A (es) Accesorio de orinal multiusos.
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
CR10090A (es) Compuestos de piperazina con accion herbicida
EA201391620A1 (ru) Фотобиореактор закрытого типа для культивирования фотосинтетических микроорганизмов
RU2009118942A (ru) Способ стимуляции регенерации тканей
CL2010000829A1 (es) Metodo para tratar plantas que comprende aplicar a las plantas una composicion liquida que contiene ente 0,3 a 300 miligramos de uno o mas ciclopropenos por litro de dicha composicion.
NO20080158L (no) Oyedraper som inneholder roflumilast
AR076275A1 (es) Uso de una tierra rara para la remocion de antimonio y bismuto

Legal Events

Date Code Title Description
FB Suspension of granting procedure